Key Words : insulin resistance, renin-angiotensin system, tumor necrosis factor-S Recent evidences suggest that insulin resistance is one of the most important factors in cardiovascular diseases. Insulin resistance is also involved in metabolic syndrome, a clustering of atherosclerotic metabolic abnormalities. In the therapeutic strategies for metabolic syndrome, the relation between the action of insulin and the renin-angiotensin system (RAS) appears to be clinically important.
cause of energy expenditure. Insulin resistance in skeletal muscle is observed in diabetic patients and animal models ( 1 − 3 ). TNF-α induces insulin resistance by inhibiting insulinmediated intracellular signaling ( 3 ). Moreover, recent reports have indicated that TNF-α is produced in skeletal muscle ( 4 − 6 ). Angiotensin II (Ang II) type 1 (AT 1 ) receptor blocker (ARB) has been shown to inhibit TNF-α production as well as insulin resistance ( 5 − 7 ). However, the mechanism of action of Ang II on regulation of TNF-α production has not been clear. In an article appearing in this issue of Hypertension Research (pp. 773 − 778), Yamaguchi et al . provide new evidence on the mechanism of action of RAS in TNF-α production in skeletal muscle using fructose-fed rats ( 8 ) . They show that the tissue level of TNF-α in rat skeletal muscle was elevated by fructose-rich chow, and that this increase was inversely related with the level of cAMP. An ARB, olmesartan, inhibited the increase in TNF-α level as well as the change in cAMP level caused by fructose-rich chow. Their results suggest that TNF-α production is negatively regulated through cAMP in skeletal muscle. Moreover, they found that a blockade of AT 1 receptor decreased TNF-α production by increasing the level of cAMP.
The possible involvement of AT 1 receptor signaling in the regulation of cAMP production is also an interesting subject. Most physiological actions of Ang II are mediated through AT 1 receptor. Ang II stimulation is often linked with phospholipase C activation, resulting in generation of diacylglycerol and inositol trisphosphate (IP3), activation of protein kinase C and intracellular Ca 2+ -mobilization through AT 1 receptor in the cardiovascular system and sympathetic neurons. However, as Yamaguchi et al . report ( 8 ) , Ang II also inhibits adenylyl cyclase/cAMP in rat heart myocytes, aorta and hepatocytes. On the other hand, Ang II stimulates cAMP production in some tissue ( 9 ) , and may enhance cAMP production via Ca 2+ /calmodulin ( 10 ). An increase in adenylyl cyclase/cAMP by a rise in available Ca 2+ has also been suggested ( 11 ) . These findings suggest a complex and variable intracellular signaling of Ang II depending on cell types.
To study the relation between RAS and TNF-α as well as other adipokines and its mechanism may provide a fresh perspective on the role of RAS in metabolic syndrome and a therapeutic strategy for insulin resistance with ARB.
